+

WO2011027060A3 - Oxytocin treatment for behavioral characteristics associated with autism and shyness disorder - Google Patents

Oxytocin treatment for behavioral characteristics associated with autism and shyness disorder Download PDF

Info

Publication number
WO2011027060A3
WO2011027060A3 PCT/FR2010/051660 FR2010051660W WO2011027060A3 WO 2011027060 A3 WO2011027060 A3 WO 2011027060A3 FR 2010051660 W FR2010051660 W FR 2010051660W WO 2011027060 A3 WO2011027060 A3 WO 2011027060A3
Authority
WO
WIPO (PCT)
Prior art keywords
autism
shyness
disorder
characteristics associated
behavioral characteristics
Prior art date
Application number
PCT/FR2010/051660
Other languages
French (fr)
Other versions
WO2011027060A2 (en
Inventor
Angela Sirigu
Elissar Andari
Original Assignee
Centre National De La Recherche Scientifique - Crns -
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique - Crns -, Universite Claude Bernard Lyon 1 filed Critical Centre National De La Recherche Scientifique - Crns -
Publication of WO2011027060A2 publication Critical patent/WO2011027060A2/en
Publication of WO2011027060A3 publication Critical patent/WO2011027060A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the use of oxytocin or an analog thereof for preventing or treating one or more behavioral characteristics associated with disorders of the autism spectrum (or autism) and shyness disorder.
PCT/FR2010/051660 2009-09-04 2010-08-05 Oxytocin treatment for behavioral characteristics associated with autism and shyness disorder WO2011027060A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09290674 2009-09-04
EP09290674.2 2009-09-04
EP09290824.3 2009-10-28
EP09290824 2009-10-28

Publications (2)

Publication Number Publication Date
WO2011027060A2 WO2011027060A2 (en) 2011-03-10
WO2011027060A3 true WO2011027060A3 (en) 2011-04-28

Family

ID=43066863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2010/051660 WO2011027060A2 (en) 2009-09-04 2010-08-05 Oxytocin treatment for behavioral characteristics associated with autism and shyness disorder

Country Status (2)

Country Link
FR (1) FR2954167A1 (en)
WO (1) WO2011027060A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113993522A (en) 2019-04-17 2022-01-28 指南针探路者有限公司 Method for treating anxiety disorders, headache disorders and eating disorders with siloxibin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030524A2 (en) * 2002-10-03 2004-04-15 Pr Pharmaceuticals Treatment of autism and similar disorders
WO2008042452A1 (en) * 2006-09-29 2008-04-10 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions comprising oxytocin or an analog for the treatment of autism
WO2008150305A1 (en) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701161D0 (en) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
SE0102184D0 (en) 2001-06-19 2001-06-19 Uvnaes Moberg Kerstin New subject matter
CN101296929A (en) 2005-10-24 2008-10-29 惠氏公司 Tricyclic compounds useful as oxytocin receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030524A2 (en) * 2002-10-03 2004-04-15 Pr Pharmaceuticals Treatment of autism and similar disorders
WO2008042452A1 (en) * 2006-09-29 2008-04-10 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions comprising oxytocin or an analog for the treatment of autism
WO2008150305A1 (en) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Thursday Abstracts", BIOLOGICAL PSYCHIATRY, vol. 63, no. 7, 13 March 2008 (2008-03-13), ELSEVIER SCIENCE, NEW YORK, NY, US, pages 1S - 111S, XP022518192, ISSN: 0006-3223, DOI: 10.1016/J.BIOPSYCH.2008.02.010 *
COSTA P T JR ET AL: "Overview: innovations in assessment using the revised NEO personality inventory", ASSESSMENT, PAR, PSYCHOLOGICAL ASSESMENT RESOURCES, US, vol. 7, no. 4, 1 December 2000 (2000-12-01), pages 325 - 327, XP009143969, ISSN: 1073-1911 *
GUASTELLA ET AL: "Oxytocin Increases Gaze to the Eye Region of Human Faces", BIOLOGICAL PSYCHIATRY, vol. 63, no. 1, 12 December 2007 (2007-12-12), ELSEVIER SCIENCE, NEW YORK, NY, US, pages 3 - 5, XP022387459, ISSN: 0006-3223, DOI: 10.1016/J.BIOPSYCH.2007.06.026 *
HOLLANDER ET AL: "Oxytocin Increases Retention of Social Cognition in Autism", BIOLOGICAL PSYCHIATRY, vol. 61, no. 4, 2 February 2007 (2007-02-02), ELSEVIER SCIENCE, NEW YORK, NY, US, pages 498 - 503, XP005871294, ISSN: 0006-3223, DOI: 10.1016/J.BIOPSYCH.2006.05.030 *
THOMPSON R ET AL: "The effects of vasopressin on human facial responses related to social communication.", PSYCHONEUROENDOCRINOLOGY, vol. 29, no. 1, January 2004 (2004-01-01), pages 35 - 48, XP002619872, ISSN: 0306-4530 *

Also Published As

Publication number Publication date
WO2011027060A2 (en) 2011-03-10
FR2954167A1 (en) 2011-06-24

Similar Documents

Publication Publication Date Title
WO2011133875A3 (en) Metalloenzyme inhibitor compounds
WO2012177603A3 (en) Metalloenzyme inhibitor compounds
IN2014DN00288A (en)
IN2014DN00286A (en)
WO2011140202A3 (en) Mif modulators
WO2012064943A3 (en) Metalloenzyme inhibitor compounds
IN2014MN01378A (en)
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014055996A3 (en) Rho kinase inhibitors
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
WO2011090738A3 (en) Type ii raf kinase inhibitors
IN2012DN00624A (en)
WO2011082245A3 (en) Metalloenzyme inhibitor compounds
WO2011053825A3 (en) Compositions and methods for the treatment or prevention of mitochondrial diseases
WO2014015210A3 (en) Microorganisms and processes for the conversion of glycerol to isoprene
WO2014145519A3 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
EP2765227A3 (en) Compositions and methods for identifying autism spectrum disorders
WO2011143640A3 (en) Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
WO2012058529A3 (en) Metalloenzyme inhibitor compounds
WO2011150457A3 (en) Haematopoietic-prostaglandin d2 synthase inhibitors
GB2455585B (en) Capsicum seeds for the treatment of eczema and dermatitis
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
WO2012082746A3 (en) Metalloenzyme inhibitor compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762971

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10762971

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载